The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with Teva under which CTI BioPharma is eligible to receive up to an additional $50M in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.
| |
| [18-January-2018] |
| SEATTLE, Jan. 18, 2018 /PRNewswire/ -- CTI BioPharma (NASDAQ and MTA:CTIC) today announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries related to the achievement of a milestone for U.S. Food and Drug Administration approval of TRISENOX® (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with Teva under which CTI BioPharma is eligible to receive up to an additional $50 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com. Forward-Looking Statements This press release includes forward-looking statements, which are within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding expectations with respect to receiving the milestone payment. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the issuers’ securities, including risks related to the satisfaction of regulatory and other requirements; the actions of regulatory bodies and other governmental authorities; other clinical trial results; changes in laws and regulations; product quality, product efficacy, study protocol, data integrity or patient safety issues; product development risks; and other risks identified in each of the issuer’s most recent filings on Forms 10-K and 10-Q and other Securities and Exchange Commission filings. CTI BioPharma Contacts: Ed Bell
View original content with multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-receive-10-million-milestone-payment-for-trisenox-300584322.html SOURCE CTI BioPharma Corp. | ||
Company Codes: NASDAQ-SMALL:CTIC, Milan:CTIC |
